Design, synthesis, a-glucosidase inhibition, pharmacokinetic, and cytotoxic studies of new indole-carbohydrazide-phenoxy-N-phenylacetamide derivatives

dc.contributor.authorHamedifar, Haleh
dc.contributor.authorMohammadi-Khanaposhtani, Maryam
dc.contributor.authorSherafati, Maedeh
dc.contributor.authorNoori, Milad
dc.contributor.authorMoazam, Ali
dc.contributor.authorHosseini, Samanesadat
dc.contributor.authorLarijani, Bagher
dc.date.accessioned2025-10-18T13:23:12Z
dc.date.created2023
dc.date.issued2023
dc.departmentBartın Üniversitesi
dc.description.abstractA new series of indole-carbohydrazide-phenoxy-N-phenylacetamide derivatives 7a-l were designed, synthesized, and screened for their alpha-glucosidase inhibitory abilities and cytotoxic effects. The results obtained in the alpha-glucosidase inhibition assay indicated that most of the synthesized derivatives displayed good to moderate inhibitory abilities (K-i values ranging from 14.65 +/- 2.54 to 37.466 +/- 6.46 mu M) when compared with the standard drug acarbose ( K-i = 42.38 +/- 5.73 mu M). Among them, 2-mehoxy-phenoxy derivatives 7l and 7h with 4-nitro and 4-chloro substituents on the phenyl ring of the N-phenylacetamide moiety, respectively, displayed the most inhibition effects. The inhibitory mechanism of these compounds was investigated by molecular docking studies. The in vitro cytotoxicity assay showed that only one compound, 2-methoxy-phenoxy derivative 7k with a 4- bromo substituent on the phenyl ring of the N-phenylacetamide moiety, exhibited moderate cytotoxicity against the human non-small-cell lung cancer cell line A549 and the rest of the compounds show almost no cytotoxicity. Further cytotoxic evaluations were also performed on compound 7k. The in silico pharmacokinetic study predicted that the selected compounds 7l and 7h are likely to be orally active.
dc.identifier.doi10.1002/ardp.202200571
dc.identifier.issn0365-6233
dc.identifier.issn1521-4184
dc.identifier.issue6
dc.identifier.orcidErdogan, Mehmet Kadir/0000-0002-1579-5737
dc.identifier.orcidTaslimi, Parham/0000-0002-3171-0633
dc.identifier.orcidGundogdu, Ramazan/0000-0001-5230-2121
dc.identifier.pmid37017555
dc.identifier.scopus2-s2.0-85151959049
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1002/ardp.202200571
dc.identifier.urihttps://hdl.handle.net/11772/22746
dc.identifier.volume356
dc.identifier.wosWOS:000964515400001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofArchiv Der Pharmazie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzWoS_20251016
dc.subjectIndole-Carbohydrazide
dc.subjectPhenoxy-N-Phenylacetamide
dc.subjectSynthesis
dc.subjectAlpha-Glucosidase Inhibitors
dc.titleDesign, synthesis, a-glucosidase inhibition, pharmacokinetic, and cytotoxic studies of new indole-carbohydrazide-phenoxy-N-phenylacetamide derivatives
dc.typeArticle
dspace.entity.typePublication

Dosyalar